Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E22.47 EPS (ttm)4.57 Insider Own0.10% Shs Outstand1.77B Perf Week-8.73%
Market Cap182.13B Forward P/E8.43 EPS next Y12.19 Insider Trans-24.59% Shs Float1.76B Perf Month-0.46%
Income7.32B PEG2.00 EPS next Q2.85 Inst Own70.10% Short Float0.76% Perf Quarter22.49%
Sales40.65B P/S4.48 EPS this Y42.30% Inst Trans0.03% Short Ratio1.63 Perf Half Y6.29%
Book/sh8.63 P/B11.91 EPS next Y16.25% ROA6.10% Target Price117.10 Perf Year22.71%
Cash/sh4.49 P/C22.91 EPS next 5Y11.23% ROE203.50% 52W Range62.55 - 113.41 Perf YTD-4.07%
Dividend5.20 P/FCF22.44 EPS past 5Y36.80% ROI21.20% 52W High-9.36% Beta0.80
Dividend %5.06% Quick Ratio0.80 Sales past 5Y10.80% Gross Margin68.60% 52W Low64.33% ATR2.47
Employees47000 Current Ratio1.00 Sales Q/Q52.20% Oper. Margin28.50% RSI (14)37.29 Volatility2.42% 2.14%
OptionableYes Debt/Eq5.70 EPS Q/Q2.20% Profit Margin18.00% Rel Volume1.44 Prev Close108.80
ShortableYes LT Debt/Eq5.39 EarningsFeb 03 BMO Payout100.60% Avg Volume8.20M Price102.79
Recom2.00 SMA20-5.34% SMA50-2.59% SMA2008.53% Volume11,841,488 Change-5.52%
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Jan-27-21 08:59AM  
Jan-26-21 05:45PM  
02:32PM  
08:45AM  
07:16AM  
07:07AM  
Jan-25-21 11:30AM  
08:30AM  
Jan-22-21 10:31AM  
Jan-20-21 05:45PM  
01:00PM  
12:15PM  
Jan-19-21 07:15AM  
Jan-15-21 09:00AM  
08:27AM  
Jan-14-21 05:45PM  
Jan-13-21 10:28AM  
09:11AM  
07:30AM  
06:03AM  
Jan-12-21 05:45PM  
04:05PM  
08:00AM  
06:45AM  
Jan-11-21 05:45PM  
Jan-09-21 06:10AM  
06:07AM  
01:00AM  
Jan-08-21 07:56PM  
10:18AM  
08:54AM  
08:47AM  
Jan-07-21 08:45AM  
08:45AM  
08:42AM  
Jan-06-21 05:32PM  
12:10PM  
11:17AM  
10:14AM  
08:00AM  
Jan-05-21 05:45PM  
10:30AM  
08:48AM  
07:40AM  
Jan-04-21 05:23PM  
Jan-03-21 04:38PM  
Dec-31-20 07:22AM  
Dec-30-20 11:10AM  
Dec-29-20 05:45PM  
04:21PM  
07:51AM  
06:04AM  
Dec-28-20 09:47AM  
Dec-25-20 06:08AM  
Dec-24-20 06:01AM  
Dec-23-20 01:12PM  
07:30AM  
07:25AM  
06:50AM  
Dec-22-20 05:45PM  
04:10PM  
03:34PM  
08:33AM  
Dec-17-20 11:15PM  
07:03AM  
Dec-16-20 05:45PM  
04:33PM  
Dec-15-20 09:46AM  
07:30AM  
07:27AM  
Dec-14-20 02:38PM  
10:33AM  
08:30AM  
Dec-12-20 12:02PM  
08:10AM  
Dec-11-20 04:59PM  
09:29AM  
07:32AM  
Dec-10-20 08:45AM  
08:21AM  
07:42AM  
06:05AM  
Dec-09-20 02:50PM  
12:18PM  
08:45AM  
Dec-06-20 01:00PM  
06:12AM  
Dec-05-20 12:45PM  
12:30PM  
Dec-04-20 08:37AM  
Dec-03-20 12:24PM  
11:38AM  
07:16AM  
Dec-02-20 03:36PM  
08:00AM  
08:00AM  
Dec-01-20 02:23PM  
08:39AM  
08:00AM  
Nov-30-20 10:56AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Option Exercise51.4225,2901,300,41276,259Dec 31 01:15 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Sale105.0025,2902,655,45050,969Dec 31 01:15 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Option Exercise51.4251,9902,673,32651,990Dec 01 05:22 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Sale105.0051,9905,458,9500Dec 01 05:22 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 20Sale99.3840,0003,975,04620,006Nov 24 05:34 PM
ALBAN CARLOSVice ChairmanNov 16Option Exercise35.88115,8304,155,980230,729Nov 18 05:04 PM
ALBAN CARLOSVice ChairmanNov 16Sale100.00115,83011,583,000114,899Nov 18 05:04 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Option Exercise57.12194,15411,089,858512,796Nov 12 05:54 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Sale97.10194,15418,851,790318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 10Sale98.0017,4261,707,74896,441Nov 12 05:56 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 09Sale95.7437,4503,585,463318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 04Sale93.614,800449,328109,067Nov 06 04:29 PM
SEVERINO MICHAELVice ChairmanNov 04Sale93.6190,6798,488,46167,281Nov 06 04:29 PM
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM